Phase 2A Multicenter Dose Escalation Study of LP-10 for the Treatment of Refractory Moderate to Severe Hemorrhagic Cystitis

Document Type

Conference Proceeding

Publication Date

4-2023

Publication Title

Journal of Urology

Abstract

NTRODUCTION AND OBJECTIVE: Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and hemorrhagic cystitis (HC). The blood loss associated with hemorrhagic cystitis can lead to surgery and can be fatal. Lipella Pharmaceuticals received orphan disease designation for HC and recently completed a phase 2a clinical trial of LP-10 for the treatment of HC. METHODS: The LP-10 Phase 2a clinical trial was a multi-center, dose-escalation study of intravesical instillation of liposomal formulation of tacrolimus at 2mg, 4 mg and 8mg. The study recruited13 subjects with moderate to severe refractory hemorrhagic cystitis. These subjects were treated with up to two courses of LP-10 bladder instillations (clinicaltrials.gov: NCT01393223). RESULTS: Fifteen subjects were screened (14 male and 1 female) and 13 enrolled. All enrolled subjects were male with mean age 67 (range 25-89 years old) with a history of prostate cancer (n=9),bladder cancer (n=2) and lymphoma (n=2). Mean duration of HC was 4 years and ranged from 1-14 years. All subjects tolerated LP-10instillations and completed the study without report of product related serious adverse events. LP-10 pharmacokinetic analysis demonstrated short duration of systemic uptake. A dose response was observed. Responder analysis evaluating cystoscopy, hematuria, and symptoms noted complete response in 3 subjects, partial response in 7 subjects and no response in 3 subjects. (NR=“no response”, PR=“partial response”, CR=“complete response”) (normalized rank,0 to 9) (Figure 1). CONCLUSIONS: The results of the Phase 2a study demonstrated safety and a signal of efficacy with dose response of LP-10 for the treatment of refractory moderate to severe HC. This is the first successfully completed trial for cancer survivors with HC and more research is needed to develop a drug treatment for hemorrhagic cystitis, a disease with great unmet need

Volume

209

Issue

4S

First Page

e1180

Last Page

e1181

Comments

American Urological Association Annual Meeting, April 28 - May 1, 2023, Chicago, IL

DOI

10.1097/JU.0000000000003360.11

Link to Full Text

Share

COinS